Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS).

Price A, Schnabel F, Chun J, Kaplowitz E, Goodgal J, Guth A, Axelrod D, Shapiro R, Mema E, Moy L, Darvishian F, Roses D.

Breast J. 2020 Jan 20. doi: 10.1111/tbj.13737. [Epub ahead of print]

PMID:
31957944
2.

Pathologic Evaluation of Breast Tissue From Transmasculine Individuals Undergoing Gender-Affirming Chest Masculinization.

Hernandez A, Schwartz CJ, Warfield D, Thomas KM, Bluebond-Langner R, Ozerdem U, Darvishian F.

Arch Pathol Lab Med. 2019 Dec 9. doi: 10.5858/arpa.2019-0316-OA. [Epub ahead of print]

PMID:
31816268
3.

Localized amyloidosis: A diagnostic pitfall in breast pathology.

Lytle A, Darvishian F, Ozerdem U.

Pathol Res Pract. 2019 Dec;215(12):152699. doi: 10.1016/j.prp.2019.152699. Epub 2019 Oct 23.

PMID:
31708371
4.

Revisiting multifocal breast cancer: a clonality study of ductal carcinoma using whole exome sequencing.

Schwartz CJ, Dolgalev I, Vasudevaraja V, Kelly S, Heguy A, Snuderl M, Cotzia P, Jour G, Darvishian F.

Hum Pathol. 2019 Dec;94:71-77. doi: 10.1016/j.humpath.2019.08.021. Epub 2019 Nov 6.

PMID:
31704365
5.

Functional analysis of RPS27 mutations and expression in melanoma.

Floristán A, Morales L, Hanniford D, Martinez C, Castellano-Sanz E, Dolgalev I, Ulloa-Morales A, Vega-Saenz de Miera E, Moran U, Darvishian F, Osman I, Kirchhoff T, Hernando E.

Pigment Cell Melanoma Res. 2019 Oct 30. doi: 10.1111/pcmr.12841. [Epub ahead of print]

PMID:
31663663
6.

Concurrent Identification of Novel EGFR-SEPT14 Fusion and ETV6-RET Fusion in Secretory Carcinoma of the Salivary Gland.

Black M, Liu CZ, Onozato M, Iafrate AJ, Darvishian F, Jour G, Cotzia P.

Head Neck Pathol. 2019 Sep 9. doi: 10.1007/s12105-019-01074-6. [Epub ahead of print]

PMID:
31502214
7.

Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).

Darvishian F, Ozerdem U, Adams S, Chun J, Pirraglia E, Kaplowitz E, Guth A, Axelrod D, Shapiro R, Price A, Troxel A, Schnabel F, Roses D.

Ann Surg Oncol. 2019 Oct;26(10):3337-3343. doi: 10.1245/s10434-019-07562-x. Epub 2019 Jun 25.

PMID:
31240590
8.

Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system.

Yoon EC, Schwartz C, Brogi E, Ventura K, Wen H, Darvishian F.

Breast J. 2019 Sep;25(5):829-837. doi: 10.1111/tbj.13352. Epub 2019 Jun 13.

PMID:
31197914
9.

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod.

Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S.

Sci Rep. 2019 Jun 12;9(1):8572. doi: 10.1038/s41598-019-42784-9.

10.

Impact of initial stage on metastatic melanoma survival.

Wilson MA, Zhong J, Rosenbaum BE, Utter K, Moran U, Darvishian F, Polsky D, Berman RS, Shapiro RL, Pavlick AC, Osman I.

Melanoma Res. 2019 Jun;29(3):281-288. doi: 10.1097/CMR.0000000000000526.

PMID:
31026246
11.

Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model.

Clendenen TV, Ge W, Koenig KL, Afanasyeva Y, Agnoli C, Brinton LA, Darvishian F, Dorgan JF, Eliassen AH, Falk RT, Hallmans G, Hankinson SE, Hoffman-Bolton J, Key TJ, Krogh V, Nichols HB, Sandler DP, Schoemaker MJ, Sluss PM, Sund M, Swerdlow AJ, Visvanathan K, Zeleniuch-Jacquotte A, Liu M.

Breast Cancer Res. 2019 Mar 19;21(1):42. doi: 10.1186/s13058-019-1126-z.

12.

The Relationship of Breast Density and Positive Lumpectomy Margins.

Gooch JC, Yoon E, Chun J, Kaplowitz E, Jubas T, Guth A, Axelrod D, Shapiro R, Darvishian F, Schnabel F.

Ann Surg Oncol. 2019 Jun;26(6):1729-1736. doi: 10.1245/s10434-019-07295-x. Epub 2019 Mar 19.

PMID:
30888516
13.

Microglandular adenosis is an advanced precursor breast lesion with evidence of molecular progression to matrix-producing metaplastic carcinoma.

Schwartz CJ, Dolgalev I, Yoon E, Osman I, Heguy A, Vega-Saenz de Miera EC, Nimeh D, Jour G, Darvishian F.

Hum Pathol. 2019 Mar;85:65-71. doi: 10.1016/j.humpath.2018.10.021. Epub 2018 Nov 11.

PMID:
30428388
14.

Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.

Giles KM, Rosenbaum BE, Berger M, Izsak A, Li Y, Illa Bochaca I, Vega-Saenz de Miera E, Wang J, Darvishian F, Zhong H, Osman I.

J Invest Dermatol. 2019 Feb;139(2):430-438. doi: 10.1016/j.jid.2018.07.031. Epub 2018 Aug 24.

PMID:
30148988
15.

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, Hernando E, Polsky D, Hanniford D, Shapiro R, Berman R, Pavlick AC, Wilson MA, Kirchhoff T, Weber JS, Zhong J, Osman I.

J Natl Cancer Inst. 2019 Feb 1;111(2):180-188. doi: 10.1093/jnci/djy086.

PMID:
29912415
16.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT.

Clin Cancer Res. 2018 Nov 1;24(21):5347-5356. doi: 10.1158/1078-0432.CCR-18-1116. Epub 2018 Jun 13.

17.

Association between Ki-67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging.

Robinson EM, Rosenbaum BE, Zhang Y, Rogers R, Tchack J, Berman RS, Darvishian F, Osman I, Shapiro RL, Shao Y, Polsky D.

J Surg Oncol. 2018 Jul;118(1):150-156. doi: 10.1002/jso.25111. Epub 2018 Jun 7.

PMID:
29878361
18.

Benign Fibromyxoid Lesion of the Breast: A Distinct Entity From Benign Spindle Cell Tumors of the Mammary Stroma?

Schwartz CJ, Schandl CA, Morse J, Ralston J, Rapkiewicz A, Darvishian F.

Int J Surg Pathol. 2018 Sep;26(6):488-493. doi: 10.1177/1066896918763901. Epub 2018 Mar 19.

PMID:
29552929
19.

Missing targets after nipple-sparing mastectomy: A multi-disciplinary approach to avoid an undesirable outcome.

Zeng J, Mercado C, Axelrod D, Guth A, Darvishian F.

Breast J. 2018 Jul;24(4):678-679. doi: 10.1111/tbj.12994. Epub 2018 Jan 8. No abstract available.

PMID:
29315983
20.

Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.

Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, Gantz M, de Pablos-Aragoneses A, Morgenstern A, Wu P, Filipescu D, Valle-Garcia D, Darvishian F, Roe JS, Davies MA, Vakoc CR, Hernando E, Bernstein E.

Mol Cell. 2017 Nov 16;68(4):731-744.e9. doi: 10.1016/j.molcel.2017.11.004.

21.

Refractory Ulcerated Necrobiosis Lipoidica: Closure of a Difficult Wound with Topical Tacrolimus.

Ginocchio L, Draghi L, Darvishian F, Ross FL.

Adv Skin Wound Care. 2017 Oct;30(10):469-472. doi: 10.1097/01.ASW.0000521867.98577.a5.

PMID:
28914682
22.

A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis.

Agrawal P, Fontanals-Cirera B, Sokolova E, Jacob S, Vaiana CA, Argibay D, Davalos V, McDermott M, Nayak S, Darvishian F, Castillo M, Ueberheide B, Osman I, Fenyö D, Mahal LK, Hernando E.

Cancer Cell. 2017 Jun 12;31(6):804-819.e7. doi: 10.1016/j.ccell.2017.05.007.

23.

Corrigendum to "Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma" (Hum Pathol 2016;57:116-25).

Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F.

Hum Pathol. 2017 May;63:222. doi: 10.1016/j.humpath.2017.03.001. Epub 2017 Apr 25. No abstract available.

PMID:
28449825
24.

MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.

Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E.

Pigment Cell Melanoma Res. 2017 May;30(3):328-338. doi: 10.1111/pcmr.12578. Epub 2017 Apr 19.

25.

Multifocal Invasive Ductal Cancer: Distinguishing Independent Tumor Foci From Multiple Satellites.

Alexander M, Acosta Gonzalez G, Malerba S, Hochman T, Goldberg JD, Darvishian F.

Int J Surg Pathol. 2017 Jun;25(4):298-303. doi: 10.1177/1066896916676586. Epub 2016 Nov 10.

PMID:
27831532
26.

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F.

Hum Pathol. 2016 Nov;57:116-125. doi: 10.1016/j.humpath.2016.07.008. Epub 2016 Jul 26. Erratum in: Hum Pathol. 2017 May;63:222.

27.

Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts.

Weiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, Krogsgaard M, Osman I, Zhong J.

J Transl Med. 2016 Oct 19;14(1):299.

28.

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.

Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E.

Cancer Med. 2016 Jun;5(6):1183-93. doi: 10.1002/cam4.667. Epub 2016 May 11.

29.

Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Esteva FJ, Moran MS, Schneider RJ.

Clin Breast Cancer. 2016 Apr;16(2):113-22.e1. doi: 10.1016/j.clbc.2015.11.006. Epub 2015 Dec 1.

30.

Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis.

Weiss S, Darvishian F, Tadepalli J, Shapiro R, Golfinos J, Pavlick A, Polsky D, Kirchhoff T, Osman I.

BMC Cancer. 2015 Nov 23;15:926. doi: 10.1186/s12885-015-1927-0.

31.

A Note of Caution: Variable Cytokeratin Staining in Sentinel Node Metastases.

Zeng J, Alexander MA, Nimeh D, Darvishian F.

Int J Surg Pathol. 2015 Oct;23(7):549-52. doi: 10.1177/1066896915596811. Epub 2015 Jul 27.

PMID:
26215220
32.

A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.

Hanniford D, Zhong J, Koetz L, Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro R, Berman R, Darvishian F, Shao Y, Osman I, Hernando E.

Clin Cancer Res. 2015 Nov 1;21(21):4903-12. doi: 10.1158/1078-0432.CCR-14-2566. Epub 2015 Jun 18.

33.

Angiosarcoma of the breast masquerading as hemangioma: exploring clinical and pathological diagnostic challenges.

Frey JD, Levine PG, Darvishian F, Shapiro RL.

Arch Plast Surg. 2015 Mar;42(2):261-3. doi: 10.5999/aps.2015.42.2.261. Epub 2015 Mar 16. No abstract available.

34.

FBXW7 modulates cellular stress response and metastatic potential through ​HSF1 post-translational modification.

Kourtis N, Moubarak RS, Aranda-Orgilles B, Lui K, Aydin IT, Trimarchi T, Darvishian F, Salvaggio C, Zhong J, Bhatt K, Chen EI, Celebi JT, Lazaris C, Tsirigos A, Osman I, Hernando E, Aifantis I.

Nat Cell Biol. 2015 Mar;17(3):322-332. doi: 10.1038/ncb3121.

35.

Identification of metastasis-suppressive microRNAs in primary melanoma.

Hanniford D, Segura MF, Zhong J, Philips E, Jirau-Serrano X, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Brown B, Osman I, Hernando E.

J Natl Cancer Inst. 2015 Feb 12;107(3). pii: dju494. doi: 10.1093/jnci/dju494. Print 2015 Mar.

36.

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N.

Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29.

37.

Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy.

Moogk D, da Silva IP, Ma MW, Friedman EB, de Miera EV, Darvishian F, Scanlon P, Perez-Garcia A, Pavlick AC, Bhardwaj N, Christos PJ, Osman I, Krogsgaard M.

J Transl Med. 2014 Dec 10;12:342. doi: 10.1186/s12967-014-0342-7.

38.

Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.

Singh B, Smith JA, Axelrod DM, Ameri P, Levitt H, Danoff A, Lesser M, de Angelis C, Illa-Bochaca I, Lubitz S, Huberman D, Darvishian F, Kleinberg DL.

Breast Cancer Res. 2014 Nov 11;16(6):463. doi: 10.1186/s13058-014-0463-1.

39.

Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?

Scanlon P, Tian J, Zhong J, Silva I, Shapiro R, Pavlick A, Berman R, Osman I, Darvishian F.

Hum Pathol. 2014 Aug;45(8):1656-63. doi: 10.1016/j.humpath.2014.04.003. Epub 2014 Apr 18.

40.

Impact of age on the management of primary melanoma patients.

Fleming NH, Tian J, Vega-Saenz de Miera E, Gold H, Darvishian F, Pavlick AC, Berman RS, Shapiro RL, Polsky D, Osman I.

Oncology. 2013;85(3):173-81. doi: 10.1159/000351499. Epub 2013 Aug 30.

41.

Breast carcinoma with tubulopapillary features: a variant of papillary carcinoma with a stronger correlation with predictors of adverse prognosis.

Darvishian F, Konno F, Qian M, Cangiarella J.

Int J Surg Pathol. 2014 Feb;22(1):47-54. doi: 10.1177/1066896913501381. Epub 2013 Sep 4.

PMID:
24008438
42.

BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez P, Morante M, Jubierre L, Zhang W, Darvishian F, Ohlmeyer M, Osman I, Zhou MM, Hernando E.

Cancer Res. 2013 Oct 15;73(20):6264-76. doi: 10.1158/0008-5472.CAN-13-0122-T. Epub 2013 Aug 15.

43.

Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.

Hale CS, Qian M, Ma MW, Scanlon P, Berman RS, Shapiro RL, Pavlick AC, Shao Y, Polsky D, Osman I, Darvishian F.

Am J Surg Pathol. 2013 Jun;37(6):882-9. doi: 10.1097/PAS.0b013e31827e50fa.

44.

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.

Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, Shao Y, Rosenberg SA, Restifo NP, Osman I, Krogsgaard M.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6973-8. doi: 10.1073/pnas.1221609110. Epub 2013 Apr 1.

45.

A note from history: landmarks in history of cancer, part 5.

Hajdu SI, Darvishian F.

Cancer. 2013 Apr 15;119(8):1450-66. doi: 10.1002/cncr.27889. Epub 2013 Jan 3.

46.

Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site.

Ma MW, Qian M, Lackaye DJ, Berman RS, Shapiro RL, Pavlick AC, Golfinos JG, Parker EC, Darvishian F, Hernando E, Shao Y, Osman I.

Neuro Oncol. 2012 Jul;14(7):849-58. doi: 10.1093/neuonc/nos113. Epub 2012 May 3.

47.

Histology-specific microRNA alterations in melanoma.

Poliseno L, Haimovic A, Segura MF, Hanniford D, Christos PJ, Darvishian F, Wang J, Shapiro RL, Pavlick AC, Berman RS, Hernando E, Zavadil J, Osman I.

J Invest Dermatol. 2012 Jul;132(7):1860-8. doi: 10.1038/jid.2011.451. Epub 2012 May 3.

48.

Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node.

Ma MW, Medicherla RC, Qian M, Vega-Saenz de Miera E, Friedman EB, Berman RS, Shapiro RL, Pavlick AC, Ott PA, Bhardwaj N, Shao Y, Osman I, Darvishian F.

Mod Pathol. 2012 Jul;25(7):1000-10. doi: 10.1038/modpathol.2012.43. Epub 2012 Mar 16.

49.

Single versus multiple primary melanomas: old questions and new answers.

Hwa C, Price LS, Belitskaya-Levy I, Ma MW, Shapiro RL, Berman RS, Kamino H, Darvishian F, Osman I, Stein JA.

Cancer. 2012 Sep 1;118(17):4184-92. doi: 10.1002/cncr.27407. Epub 2012 Jan 13.

50.

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, Pavlick AC, Darvishian F, Christos P, Mazumdar M, Osman I, Polsky D.

PLoS One. 2012;7(1):e29336. doi: 10.1371/journal.pone.0029336. Epub 2012 Jan 3.

Supplemental Content

Loading ...
Support Center